Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。